Pulmonary Embolism Guidelines
Diagnosis
Base your diagnostic approach on clinical probability assessment using validated prediction rules (Wells or revised Geneva score), followed by D-dimer testing in low-to-intermediate probability patients, with CTPA as the definitive imaging modality 1.
Diagnostic Algorithm by Clinical Probability:
High Clinical Probability:
- Initiate anticoagulation immediately while diagnostic workup proceeds 1
- Proceed directly to CTPA (do not measure D-dimer—normal results don't safely exclude PE) 1
- In hemodynamically unstable patients: perform bedside echocardiography or emergency CTPA depending on availability 1
Low-to-Intermediate Clinical Probability:
- Measure D-dimer using highly sensitive assay 1
- If D-dimer negative: PE excluded, no further testing needed 1
- If D-dimer positive: proceed to CTPA 1
- Consider age-adjusted D-dimer cutoffs to improve specificity 2
Imaging Interpretation:
- Accept PE diagnosis if CTPA shows segmental or more proximal filling defect in intermediate/high probability patients 1
- Reject PE diagnosis if CTPA normal in low/intermediate probability patients 1
- Accept VTE diagnosis if compression ultrasound shows proximal DVT in patients with suspected PE 1
Avoid These Diagnostic Pitfalls:
Risk Stratification
Immediately stratify all patients based on hemodynamic stability to identify high-risk PE, then further classify stable patients into intermediate- and low-risk categories 1.
Risk Categories:
High-Risk PE (Hemodynamically Unstable):
- Sustained hypotension (SBP <90 mmHg for ≥15 minutes)
- Requirement for vasopressors
- Cardiac arrest
- Obstructive shock
Intermediate-Risk PE:
- Hemodynamically stable but with evidence of RV dysfunction (imaging) and/or elevated cardiac biomarkers
Low-Risk PE:
- Hemodynamically stable without RV dysfunction or biomarker elevation
Acute Phase Treatment
High-Risk PE
Administer systemic thrombolytic therapy immediately for high-risk PE—this is the definitive Class I recommendation 1.
Treatment Protocol:
- Initiate IV unfractionated heparin with weight-adjusted bolus without delay 1
- Administer systemic thrombolysis (Class I, Level B) 1
- Consider norepinephrine and/or dobutamine for hemodynamic support 1
If Thrombolysis Contraindicated or Failed:
- Surgical pulmonary embolectomy (Class I recommendation) 1
- Percutaneous catheter-directed treatment (Class IIa) 1
- ECMO may be considered in combination with surgical/catheter-directed treatment for refractory circulatory collapse 1
Intermediate- and Low-Risk PE
Prefer NOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) over vitamin K antagonists for oral anticoagulation in eligible patients 1.
Anticoagulation Protocol:
- Initiate anticoagulation immediately in high/intermediate clinical probability patients while workup proceeds 1
- If starting with parenteral anticoagulation: prefer LMWH or fondaparinux over UFH (Class I, Level A) 1
- When initiating oral anticoagulation: choose NOAC over VKA (Class I, Level A) 1
- If using VKA: overlap with parenteral anticoagulation until INR 2.5 (range 2.0-3.0) achieved 1
Do NOT routinely use systemic thrombolysis in intermediate- or low-risk PE (Class III, Level B) 1. Reserve thrombolysis for rescue therapy if hemodynamic deterioration occurs on anticoagulation 1.
NOAC Contraindications:
Duration of Anticoagulation
All patients require therapeutic anticoagulation for minimum 3 months 1.
Decision Algorithm for Extended Therapy:
Stop at 3 Months:
- First PE secondary to major transient/reversible risk factor (surgery, trauma, immobilization) 1
Continue Indefinitely:
- Recurrent VTE (≥1 previous PE or DVT episode) not related to transient risk factor 1
- Unprovoked PE in patients at low bleeding risk 3
- Active cancer (ongoing strong risk factor) 3
- Antiphospholipid antibody syndrome (use VKA, not NOAC) 1
For Extended Anticoagulation:
- Reassess drug tolerance, adherence, hepatic/renal function, and bleeding risk at regular intervals 1
Special Populations
Pregnancy
Use therapeutic fixed-dose LMWH based on early pregnancy weight for pregnant women without hemodynamic instability 1.
Critical Safety Points:
- Do not insert spinal/epidural needle within 24 hours of last LMWH dose 1
- Do not administer LMWH within 4 hours of epidural catheter removal 1
- Absolutely do not use NOACs during pregnancy or lactation 1
- Perform formal diagnostic assessment with validated methods if PE suspected 1
Inferior Vena Cava Filters
Do NOT routinely use IVC filters (Class III, Level A) 1.
Consider IVC Filters Only For:
- Acute PE with absolute contraindications to anticoagulation (Class IIa) 1
- PE recurrence despite therapeutic anticoagulation (Class IIa) 1
Early Discharge and Outpatient Management
Carefully selected low-risk PE patients should be considered for early discharge with home treatment if proper outpatient care and anticoagulation can be provided (Class IIa, Level A) 1.
Post-PE Follow-Up
Routinely re-evaluate all patients 3-6 months after acute PE 1.
Screen for Chronic Complications:
- Refer symptomatic patients with mismatched perfusion defects on V/Q scan beyond 3 months to pulmonary hypertension/CTEPH expert center 1
- Consider echocardiography, natriuretic peptides, and cardiopulmonary exercise testing 1
- Implement integrated care model to ensure optimal transition from hospital to ambulatory care 1
Key Clinical Pitfalls to Avoid
- Never delay anticoagulation in high/intermediate probability patients waiting for imaging 1
- Never use D-dimer to exclude PE in high clinical probability patients 1
- Never routinely thrombolyze intermediate-risk PE—reserve for hemodynamic deterioration 1
- Never use NOACs in severe renal impairment, pregnancy, or antiphospholipid syndrome 1
- Never place IVC filters routinely—only for absolute anticoagulation contraindications 1